Keros Therapeutics, Inc. Insider Trading for March 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Keros Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Keros Therapeutics, Inc. for March 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 15 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Option Exercise | M | 0.48 | 1,000 | 480 | 101,211 | |
| Mar 15 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 64.86 | 605 | 39,240 | 0 | 605 to 0 (-100.00 %) |
| Mar 15 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 64.09 | 395 | 25,316 | 605 | 1,000 to 605 (-39.50 %) |
| Mar 15 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Buy | M | 0.48 | 1,000 | 480 | 1,000 | 0 to 1,000 |
| Mar 15 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.30 | 5,300 | 1,590 | 140,305 | |
| Mar 15 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 65.47 | 4 | 262 | 61,191 | 61.2 K to 61.2 K (-0.01 %) |
| Mar 15 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 64.72 | 3,557 | 230,209 | 61,195 | 64.8 K to 61.2 K (-5.49 %) |
| Mar 15 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 63.99 | 1,739 | 111,279 | 64,752 | 66.5 K to 64.8 K (-2.62 %) |
| Mar 15 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.30 | 5,300 | 1,590 | 66,491 | 61.2 K to 66.5 K (+8.66 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.03 | 126 | 7,312 | 420,825 | 421 K to 420.8 K (-0.03 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.03 | 193 | 11,200 | 629,987 | 630.2 K to 630 K (-0.03 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 57.21 | 553 | 31,637 | 420,951 | 421.5 K to 421 K (-0.13 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 57.21 | 847 | 48,457 | 630,180 | 631 K to 630.2 K (-0.13 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 56.18 | 895 | 50,281 | 421,504 | 422.4 K to 421.5 K (-0.21 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 56.18 | 1,376 | 77,304 | 631,027 | 632.4 K to 631 K (-0.22 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 55.21 | 1,932 | 106,666 | 422,399 | 424.3 K to 422.4 K (-0.46 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 55.21 | 2,962 | 163,532 | 632,403 | 635.4 K to 632.4 K (-0.47 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 54.22 | 1,086 | 58,883 | 424,331 | 425.4 K to 424.3 K (-0.26 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 54.22 | 1,662 | 90,114 | 635,365 | 637 K to 635.4 K (-0.26 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.88 | 496 | 29,204 | 425,417 | 425.9 K to 425.4 K (-0.12 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.88 | 761 | 44,808 | 637,027 | 637.8 K to 637 K (-0.12 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 57.79 | 1,894 | 109,454 | 425,913 | 427.8 K to 425.9 K (-0.44 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 57.79 | 2,903 | 167,764 | 637,788 | 640.7 K to 637.8 K (-0.45 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 56.95 | 1,958 | 111,508 | 427,807 | 429.8 K to 427.8 K (-0.46 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 56.95 | 3,004 | 171,078 | 640,691 | 643.7 K to 640.7 K (-0.47 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 55.91 | 518 | 28,961 | 429,765 | 430.3 K to 429.8 K (-0.12 %) |
| Mar 05 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 55.91 | 793 | 44,337 | 643,695 | 644.5 K to 643.7 K (-0.12 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 61.90 | 90 | 5,571 | 430,283 | 430.4 K to 430.3 K (-0.02 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 61.90 | 138 | 8,542 | 644,488 | 644.6 K to 644.5 K (-0.02 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 60.61 | 361 | 21,880 | 430,373 | 430.7 K to 430.4 K (-0.08 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 60.61 | 554 | 33,578 | 644,626 | 645.2 K to 644.6 K (-0.09 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 60.05 | 686 | 41,194 | 430,734 | 431.4 K to 430.7 K (-0.16 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 60.05 | 1,052 | 63,173 | 645,180 | 646.2 K to 645.2 K (-0.16 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.90 | 714 | 42,055 | 431,420 | 432.1 K to 431.4 K (-0.17 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 58.90 | 1,095 | 64,496 | 646,232 | 647.3 K to 646.2 K (-0.17 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 57.93 | 2,377 | 137,700 | 432,134 | 434.5 K to 432.1 K (-0.55 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 57.93 | 3,644 | 211,097 | 647,327 | 651 K to 647.3 K (-0.56 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 67.60 | 30 | 2,028 | 434,511 | 434.5 K to 434.5 K (-0.01 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 67.60 | 46 | 3,110 | 650,971 | 651 K to 651 K (-0.01 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 66.04 | 516 | 34,077 | 434,541 | 435.1 K to 434.5 K (-0.12 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 66.04 | 792 | 52,304 | 651,017 | 651.8 K to 651 K (-0.12 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 65.28 | 479 | 31,269 | 435,057 | 435.5 K to 435.1 K (-0.11 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 65.29 | 734 | 47,923 | 651,809 | 652.5 K to 651.8 K (-0.11 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 64.09 | 406 | 26,021 | 435,536 | 435.9 K to 435.5 K (-0.09 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 64.09 | 625 | 40,056 | 652,543 | 653.2 K to 652.5 K (-0.10 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 63.22 | 1,169 | 73,904 | 435,942 | 437.1 K to 435.9 K (-0.27 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 63.22 | 1,794 | 113,417 | 653,168 | 655 K to 653.2 K (-0.27 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 62.11 | 1,473 | 91,488 | 437,111 | 438.6 K to 437.1 K (-0.34 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 62.11 | 2,257 | 140,182 | 654,962 | 657.2 K to 655 K (-0.34 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 61.33 | 1,050 | 64,397 | 438,584 | 439.6 K to 438.6 K (-0.24 %) |
| Mar 03 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 61.33 | 1,608 | 98,619 | 657,219 | 658.8 K to 657.2 K (-0.24 %) |
| Mar 01 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.11 | 33,200 | 3,652 | 9,996 | |
| Mar 01 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.11 | 33,200 | 3,652 | 61,191 | 28 K to 61.2 K (+118.61 %) |